As J&J's oral IL-23 takes on So­tyk­tu, one-year fol­low-up da­ta show dura­bil­i­ty: #AAD24

John­son & John­son un­veiled long-term ex­ten­sion da­ta on Sat­ur­day for a pro­gram it hopes can com­pete with Bris­tol My­ers Squibb’s So­tyk­tu in plaque pso­ri­a­sis. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER